Arch Truth
GUIDANCE
Ozanimod Reduces Severe Relapses in Multiple Sclerosis More Than Interferon Beta-1a
Treatments were evaluated for either 1 year (SUNBEAM) or 2 years (RADIANCE).
October 11, 2018